How and why central aortic pressure (cBP) monitoring should be integrated into clinical development programs
How and why central aortic pressure (cBP) monitoring should be integrated into clinical development programs
Non-Invasive Central Aortic Pressure Monitoring for Clinical Trials
Drug and medical device development costs increase exponentially as development programs advance to regulatory approval and commercialization. For products targeting cardiovascular disease, incorporation of central aortic blood pressure measurement and monitoring into clinical trials has the potential to improve key decisions during development (go/no go, endpoints, population characteristics, benefit-risk profile, dosing, etc.) and enhance the likelihood of both regulatory and commercial success. Based on current technology, the availability of a non-invasive dual arterial pressure measurement system, the compelling clinical rationale and the extensive clinical published research, incorporation of central aortic pressure monitoring into clinical trials, which is complementary to continued reliance on brachial pressure monitoring should be part of drug and medical device development programs for hypertension and other cardiovascular disorders.
Download the White Paper
Non-Invasive Central Aortic Pressure Monitoring for Clinical Trials
Drug and medical device development costs increase exponentially as development programs advance to regulatory approval and commercialization. For products targeting cardiovascular disease, incorporation of central aortic blood pressure measurement and monitoring into clinical trials has the potential to improve key decisions during development (go/no go, endpoints, population characteristics, benefit-risk profile, dosing, etc.) and enhance the likelihood of both regulatory and commercial success. Based on current technology, the availability of a non-invasive dual arterial pressure measurement system, the compelling clinical rationale and the extensive clinical published research, incorporation of central aortic pressure monitoring into clinical trials, which is complementary to continued reliance on brachial pressure monitoring should be part of drug and medical device development programs for hypertension and other cardiovascular disorders.